Fox Chase Cancer Center-ko ikertzaileekin lankidetzan egindako argitalpenak (17)

2023

  1. Five-Year Survival Outcomes with Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227

    Journal of Clinical Oncology, Vol. 41, Núm. 6, pp. 1200-1212

  2. Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

    Annals of Oncology, Vol. 34, Núm. 2, pp. 173-185

  3. Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial

    ESMO Open, Vol. 8, Núm. 6

  4. Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817

    Journal of Thoracic Oncology, Vol. 18, Núm. 1, pp. 79-92

  5. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1

    Journal of Thoracic Oncology, Vol. 18, Núm. 8, pp. 1055-1069

  6. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

    New England Journal of Medicine, Vol. 389, Núm. 22, pp. 2063-2075

  7. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2893-2903

2022

  1. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    Journal of Thoracic Oncology, Vol. 17, Núm. 2, pp. 289-308

  2. Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

    Nature medicine, Vol. 28, Núm. 4, pp. 752-765

2018

  1. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden

    New England Journal of Medicine, Vol. 378, Núm. 22, pp. 2093-2104

2017

  1. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer

    New England Journal of Medicine, Vol. 376, Núm. 25, pp. 2415-2426

  2. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III Trials (CheckMate 017 and CheckMate 057)

    Journal of Clinical Oncology, Vol. 35, Núm. 35, pp. 3924-3933

  3. Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer

    Lung Cancer, Vol. 112, pp. 181-187

2015

  1. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    New England Journal of Medicine, Vol. 373, Núm. 17, pp. 1627-1639

2009

  1. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin

    Journal of Thoracic Oncology, Vol. 4, Núm. 11, pp. 1397-1403

1999

  1. Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion

    Annals of Oncology, Vol. 10, Núm. 3, pp. 339-344

1998

  1. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion

    British Journal of Cancer, Vol. 78, Núm. 10, pp. 1329-1336